web analytics
6.2 C
Munich
Wednesday, December 1, 2021

Vyome Therapeutics, Inc.; The Rise of Livechain, Inc (OTCMKTS: LICH)

Livechain, Inc (OTCMKTS: LICH) has been rocketing up the charts in recent days hitting a high of $0.0598 earlier in the week and retracing some before the weekend. The stock is getting noticed after the Company filed their annual report on Friday which confirmed that Vyome Therapeutics, Inc is the new controlling shareholder of the Company with 70.08% of the companies issued and outstanding shares. At the time of transfer, Venkat Nelabhotla, Chief Executive Officer and Director of Vyome Therapeutics, Inc., also became Chief Executive Officer and Director of Livechain, Inc. 

Reverse Merger stocks (RM) are easily among the most exciting and explosive stocks in small caps rivaling only biotech’s in their ability to make historic gains. LICH is the perfect merger candidate; a clean shell with virtually no debt and the new Company Vyome Therapeutics is a clinical-stage company developing locally-acting, next generation therapeutics for immuno-inflammatory diseases. Vyome’s lead clinical drug candidate, VB-1953, is a first-in-class, topical, bactericidal small molecule with a novel mechanism of action in acne. In 2019, the acne treatment market was valued at nearly 11 billion U.S. dollars, according to market research company NMSC. However, until 2030 it is expected to increase to over 15 billion U.S. dollars. Regarding the global skin care market in total, the United States and Japan have the highest shares. 

Livechain, Inc (OTCMKTS: LICH) is a clean shell with just $64k in total liabilities operating out of Reno, Nevada. Management spent the summer of 2021 filing previous annual reports and the attorneys letter in June. The Company is now pink current with just 185,145,941 shares outstanding representing a total market valuation of $4,850,824. LiveChain, Inc. was originally formed as Eastern Star Mining Company, incorporated under the laws of the State of Idaho in 1906. In 1989 the predecessor merged into a newly-formed Nevada corporation as Eastern Star Mining, Inc. Immediately thereafter, the holder of a majority of the outstanding common stock transferred control of the corporation. After a number of incarnations, the name change to LiveChain, Inc. was approved by a majority of the shareholders of the Company on August 12, 2019 

On August 31, 2021, the board of directors, by consent entered a Stock Purchase agreement with Vyome Therapeutics, Inc., to sell to Vyome Therapeutics, Inc., 986,919 of the 996,919 of the company’s A-1 preferred shares. On the date of closing, Vyome Therapeutics, Inc., purchased 996,919 shares of Livechain, Inc.’s, A-1 proffered stock, assuming 70.08% of the companies issued and outstanding shares. At the time of transfer, Venkat Nelabhotla, Chief Executive Officer and Director of Vyome Therapeutics, Inc., also became Chief Executive Officer and Director of Livechain, Inc. 

Vyome Therapeutics is a clinical-stage company developing locally-acting, next generation therapeutics for immuno-inflammatory diseases with several drugs currently under development. Vyome works to treat inflammatory diseases using locally-acting, novel and next generation therapeutic solutions with validated mechanisms of action and effective formulations for site-targeted applications. With this approach to drug development, Vyome is working to develop safer and more effective alternatives to standards of care in multifactorial diseases of high unmet need which are underpinned by inflammation. 

Vyome’s lead clinical drug candidate, VB-1953, is a first-in-class, topical, bactericidal small molecule with a novel mechanism of action in acne. VB-1953 reduces inflammatory lesions in C. acnes by blocking inflammatory cytokine production through TLR-MD2 inhibition and has demonstrated the ability to treat antibiotic-resistant C. acnes strains. VB-1953 is the first bactericidal drug candidate to be tested for the treatment of C. acnes. VB-1953 is delivered topically with a microtechnology gel system that ensures the drug is retained at the site of infection and minimizes systemic exposure. Acne caused by antibacterial-resistant C. acnes currently poses an emerging and unmet need for patients worldwide, with a potential $2B market opportunity in the US alone. 

To Find out the inside Scoop on LICH Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

LICH

Last year the Company reported positive data from its Phase 2 trial of VB-1953, a firstin-class topical bactericidal and TLR-MD2 inhibitor being developed for the treatment of moderate to severe inflammatory facial acne vulgaris. Results from the trial demonstrated a statistically significant difference in the primary endpoint, the mean absolute change in inflammatory lesions at week 12, for VB 1953, when applied once a day (QD) vs. combined vehicle group (p <0.012). In the comparison between the VB1953 QD arm versus vehicle QD, the mean absolute change in the inflammatory lesions at week 12 in the intent to treat (ITT) group showed 20.4 and 17.8 respectively, with p<0.003, and 20.4 and 16.6 respectively in per protocol group with p<0.001. In addition, VB-1953 exhibited an excellent safety profile and there were no drug related adverse or serious adverse events. “These results demonstrate that VB-1953, with its dual mechanism of action directly killing resistant and non-resistant C. acnes strains while blocking inflammation through TLR-MD2 inhibition, has the potential to become a safe and effective topical treatment for facial acne and an alternative to oral, systemic drugs,” said Dr. Shiladitya Sengupta, scientific co-founder of Vyome. 

The Phase 2 randomized, multicenter, double-blind, dose-ranging study was designed to evaluate the safety and efficacy of VB-1953 topical gel when applied once daily and twice daily for 12 weeks in subjects with moderate to severe inflammatory facial acne vulgaris. The Company enrolled 471 patients across 13 trial sites in the U.S.  Once daily (QD) application was found to be as effective as twice daily application in the mean absolute change in the inflammatory lesions. 

Venkat Nelabhotla, Chief Executive Officer of Vyome Therapeutics, said at the time: “We are very pleased to have met the primary endpoint of the study, and to demonstrate the continued safety of the molecule. Patients need a highly effective drug, and our data shows a very high response, which is encouraging as we plan to advance to Phase 3 with a once daily dose. We look forward to delivering a next-generation solution to patients.” 

Although the study was not powered to test for significance in secondary end points, the drug (VB 1953 QD group) achieved a 66.6% mean reduction in inflammatory lesions at week 12 with p<0.020 in ITT and p<0.004 per protocol group versus vehicle group, and a 49.6% successful improvement in the IGA score (minimum two-grade improvement and achieving clear or almost clear IGA score at week 12) with p<0.361 in ITT group and p<0.069 per protocol group versus vehicle group. 

Acne is a skin condition caused by a clogging of hair follicles with dead skin or oils. This condition is also known as acne vulgaris. Acne is a very common medical condition and a majority of the world’s population has been affected by acne in their life. There are a variety of treatment options and skin care products used for acne. Despite acne being a common skin condition, recent estimates indicate that acne treatment products contributed a small amount to the overall sales of skin care products globally.  In 2019, the acne treatment market was valued at nearly 11 billion U.S. dollars, according to market research company NMSC. However, until 2030 it is expected to increase to over 15 billion U.S. dollars. Regarding the global skin care market in total, the United States and Japan have the highest shares. 

 

For More on LICH Subscribe Right Now!

LICH has been rocketing up the charts recently hitting a high of $0.0598 earlier in the week and retracing some before the weekend. The stock is getting noticed after the Company filed their annual report on Friday which confirmed that Vyome Therapeutics, Inc is the new controlling shareholder of the Company with 70.08% of the companies issued and outstanding shares. At the time of transfer, Venkat Nelabhotla, Chief Executive Officer and Director of Vyome Therapeutics, Inc., also became Chief Executive Officer and Director of Livechain, Inc. Reverse Merger stocks (RM) are easily among the most exciting and explosive stocks in small caps rivaling only biotech’s in their ability to make historic gains. LICH is the perfect merger candidate; a clean shell with virtually no debt and the new Company Vyome Therapeutics is a clinical-stage company developing locally-acting, next generation therapeutics for immuno-inflammatory diseases. Vyome’s lead clinical drug candidate, VB-1953, is a first-in-class, topical, bactericidal small molecule with a novel mechanism of action in acne. In 2019, the acne treatment market was valued at nearly 11 billion U.S. dollars, according to market research company NMSC. However, until 2030 it is expected to increase to over 15 billion U.S. dollars. Regarding the global skin care market in total, the United States and Japan have the highest shares. LICH is currently under heavy accumulation and is starting to get noticed by some heavy hitters in small caps who are looking for a break over $0.0598 for confirmation of the next leg up. A break over and its blue skies ahead. We will be updating on LICH when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with LICH.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in LICH either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.